Selected research
Market Outlook & Growth Opportunities
Global Equine Influenza Vaccine Market Outlook and Growth Opportunities 2026
Market perspective
The global Equine Influenza Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Equine Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Equine Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Equine Influenza Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Equine Influenza Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Equine Influenza Vaccine market include Zoetis, Merck Animal Health and Boehringer Ingelheim Vetmedica, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Equine Influenza Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Equine Influenza Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Equine Influenza Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Equine Influenza Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Equine Influenza Vaccine Segment by Company
Zoetis
Merck Animal Health
Boehringer Ingelheim Vetmedica
Equine Influenza Vaccine Segment by Type
Liquid
Powder
Equine Influenza Vaccine Segment by Application
Home
Pet Clinic
Others
Equine Influenza Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Equine Influenza Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Equine Influenza Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Equine Influenza Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Equine Influenza Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Equine Influenza Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Equine Influenza Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Equine Influenza Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Equine Influenza Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Equine Influenza Vaccine industry.
Chapter 3: Detailed analysis of Equine Influenza Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Equine Influenza Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Equine Influenza Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid
- Powder
Applications
- Home
- Pet Clinic
- Others
Companies covered
- Zoetis
- Merck Animal Health
- Boehringer Ingelheim Vetmedica
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Equine Influenza Vaccine Sales Value (2021-2032)
- 1.2.2 Global Equine Influenza Vaccine Sales Volume (2021-2032)
- 1.2.3 Global Equine Influenza Vaccine Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Equine Influenza Vaccine Market Dynamics
- 2.1 Equine Influenza Vaccine Industry Trends
- 2.2 Equine Influenza Vaccine Industry Drivers
- 2.3 Equine Influenza Vaccine Industry Opportunities and Challenges
- 2.4 Equine Influenza Vaccine Industry Restraints
3 Equine Influenza Vaccine Market by Company
- 3.1 Global Equine Influenza Vaccine Company Revenue Ranking in 2025
- 3.2 Global Equine Influenza Vaccine Revenue by Company (2021-2026)
- 3.3 Global Equine Influenza Vaccine Sales Volume by Company (2021-2026)
- 3.4 Global Equine Influenza Vaccine Average Price by Company (2021-2026)
- 3.5 Global Equine Influenza Vaccine Company Ranking (2024-2026)
- 3.6 Global Equine Influenza Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global Equine Influenza Vaccine Company Product Type and Application
- 3.8 Global Equine Influenza Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Equine Influenza Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Equine Influenza Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Equine Influenza Vaccine Market by Type
- 4.1 Equine Influenza Vaccine Type Introduction
- 4.1.1 Liquid
- 4.1.2 Powder
- 4.2 Global Equine Influenza Vaccine Sales Volume by Type
- 4.2.1 Global Equine Influenza Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Equine Influenza Vaccine Sales Volume by Type (2021-2032)
- 4.2.3 Global Equine Influenza Vaccine Sales Volume Share by Type (2021-2032)
- 4.3 Global Equine Influenza Vaccine Sales Value by Type
- 4.3.1 Global Equine Influenza Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Equine Influenza Vaccine Sales Value by Type (2021-2032)
- 4.3.3 Global Equine Influenza Vaccine Sales Value Share by Type (2021-2032)
5 Equine Influenza Vaccine Market by Application
- 5.1 Equine Influenza Vaccine Application Introduction
- 5.1.1 Home
- 5.1.2 Pet Clinic
- 5.1.3 Others
- 5.2 Global Equine Influenza Vaccine Sales Volume by Application
- 5.2.1 Global Equine Influenza Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Equine Influenza Vaccine Sales Volume by Application (2021-2032)
- 5.2.3 Global Equine Influenza Vaccine Sales Volume Share by Application (2021-2032)
- 5.3 Global Equine Influenza Vaccine Sales Value by Application
- 5.3.1 Global Equine Influenza Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Equine Influenza Vaccine Sales Value by Application (2021-2032)
- 5.3.3 Global Equine Influenza Vaccine Sales Value Share by Application (2021-2032)
6 Equine Influenza Vaccine Regional Sales and Value Analysis
- 6.1 Global Equine Influenza Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Equine Influenza Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Equine Influenza Vaccine Sales by Region: 2021-2026
- 6.2.2 Global Equine Influenza Vaccine Sales by Region (2027-2032)
- 6.3 Global Equine Influenza Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Equine Influenza Vaccine Sales Value by Region (2021-2032)
- 6.4.1 Global Equine Influenza Vaccine Sales Value by Region: 2021-2026
- 6.4.2 Global Equine Influenza Vaccine Sales Value by Region (2027-2032)
- 6.5 Global Equine Influenza Vaccine Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Equine Influenza Vaccine Sales Value (2021-2032)
- 6.6.2 North America Equine Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Equine Influenza Vaccine Sales Value (2021-2032)
- 6.7.2 Europe Equine Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Equine Influenza Vaccine Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Equine Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Equine Influenza Vaccine Sales Value (2021-2032)
- 6.9.2 South America Equine Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Equine Influenza Vaccine Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Equine Influenza Vaccine Sales Value Share by Country, 2025 VS 2032
7 Equine Influenza Vaccine Country-level Sales and Value Analysis
- 7.1 Global Equine Influenza Vaccine Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Equine Influenza Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Equine Influenza Vaccine Sales by Country (2021-2032)
- 7.3.1 Global Equine Influenza Vaccine Sales by Country (2021-2026)
- 7.3.2 Global Equine Influenza Vaccine Sales by Country (2027-2032)
- 7.4 Global Equine Influenza Vaccine Sales Value by Country (2021-2032)
- 7.4.1 Global Equine Influenza Vaccine Sales Value by Country (2021-2026)
- 7.4.2 Global Equine Influenza Vaccine Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.9.2 France Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.16.2 China Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.19.2 India Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Equine Influenza Vaccine Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Equine Influenza Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Equine Influenza Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Zoetis
- 8.1.1 Zoetis Company Information
- 8.1.2 Zoetis Business Overview
- 8.1.3 Zoetis Equine Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Zoetis Equine Influenza Vaccine Product Portfolio
- 8.1.5 Zoetis Recent Developments
- 8.2 Merck Animal Health
- 8.2.1 Merck Animal Health Company Information
- 8.2.2 Merck Animal Health Business Overview
- 8.2.3 Merck Animal Health Equine Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Merck Animal Health Equine Influenza Vaccine Product Portfolio
- 8.2.5 Merck Animal Health Recent Developments
- 8.3 Boehringer Ingelheim Vetmedica
- 8.3.1 Boehringer Ingelheim Vetmedica Company Information
- 8.3.2 Boehringer Ingelheim Vetmedica Business Overview
- 8.3.3 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Product Portfolio
- 8.3.5 Boehringer Ingelheim Vetmedica Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Equine Influenza Vaccine Value Chain Analysis
- 9.1.1 Equine Influenza Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Equine Influenza Vaccine Sales Mode & Process
- 9.2 Equine Influenza Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Equine Influenza Vaccine Distributors
- 9.2.3 Equine Influenza Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst